CompletedPhase 2

H-22411: BOTOX® for Peyronie's Disease

United States12 participantsStarted 2009-08-07

Plain-language summary

Peyronie's disease is a condition in which a plaque, or hard lump, forms on the penis. It causes hardened tissue, pain, and an abnormal bending in the penis. These symptoms are more severe during an erection. Significant bending of the penis can result in pain, poor erections, and an inability to engage in sexual intercourse. This disease affects about 3% of the male population. The average age of onset of this disease is 57 years old. The cause of the disease is unknown. However, many believe that it may be due to trauma to the penis (such as injury or extremely vigorous sexual activity).

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects with stable Peyronie's plaques. * Males at least 18 years of age * Must give informed consent. Exclusion Criteria: * Subjects in the active phase of Peyronie's disease. * Subjects with less than 1 year history of Peyronie's disease. * Subjects taking oral medications for Peyronie's disease which include Trental, Viagra, vitamin E, colchicines, L-arginine, and tamoxifen. There will be a 2 week wash-out period if patients are on these medications. * Subjects with more than 1 penile plaque will be excluded from the study. * Subjects with calcified plaques demonstrated by ultrasound will be excluded from the study. * Known allergy or sensitivity to any components of the study medication (botulinum toxin A), anesthetics, or any other product associated with the treatment and general study procedures. * Any medical condition or neuromuscular disorder that may put the patient at increased risk with exposure to botulinum toxin A (BTX-A), including myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis. * Patient taking aminoglycosides or any drug known to interfere with neuromuscular transmission. * Patient has hemophilia or other clotting factor deficiencies or disorders that cause bleeding diathesis. * Patient must not be taking aspirin, non-steroidal anti-inflammatory drugs, or Coumadin for 7 or more days prior to Botox injection. * Episode of unstable angina pectoris, myocardial infarction, transient ischemic attack, or cereb…

What they're measuring

Average Percent Change of Penile Curvature in Degrees

Timeframe: Baseline (Pre-Treatment Screening Visit) to end of treatment at week 16

Trial details

NCT IDNCT00812838

SponsorMohit Khera

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-02-15

Results submitted2020-01-13